Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

28 janv. 2025 10h00 HE | Source: AlphaMeld Corporation

AlphaMeld Corporation Expands Collaboration with Kyowa Kirin for Enterprise-Wide Access to Drug Discovery Platform

GUILFORD, Conn., Jan. 28, 2025 (GLOBE NEWSWIRE) -- AlphaMeld Corporation, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to...
13 janv. 2025 10h00 HE | Source: InveniAI LLC

InveniAI Announces Launch of AlphaMeld Corporation and Major Milestone Updates to Reflect Cutting-Edge Innovation in AI-Driven Drug Discovery

GUILFORD, Conn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize...
19 févr. 2024 02h00 HE | Source: InveniAI LLC

InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery

Teams will work together by leveraging InveniAI's technology platform to identify, evaluate, and optimize novel targets across Ono’s diseases of interestOno will access InveniAI’s AI platform...
04 avr. 2023 08h43 HE | Source: InveniAI LLC

InveniAI's AlphaMeld Platform Debuts the Addition of ChatAlphaMeld™, A Powerful Tool Designed to Scale Target and Drug Discovery and Development

Powered by GPT-4, ChatAlphaMeld enables user interaction across functional stakeholders to automate hypothesis generation and prioritization Integrated into the AlphaMeld workflow, ChatAlphaMeld is...
16 déc. 2021 08h10 HE | Source: InveniAI LLC

InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas

Collaboration enables Kyowa Kirin's R&D team to access InveniAI's data-driven discovery platform in expanded therapeutic areasInveniAI's AlphaMeld® platform to provide unique Translational Edge...